Amgen reports positive Phase 3 results for Sjögren's drug; Novartis announces $900M radioligand partnership

Amgen said its CD40 ligand antagonist dazodalibep met the primary endpoint in a Phase 3 trial for Sjögren's syndrome, marking a notable achievement for the company.

Novartis disclosed a $900 million agreement to secure a radioligand therapy platform, highlighting its continued focus on targeted cancer treatments.

The briefing also mentioned activity from Boehringer, Envisagenics, Ionis, Otsuka, Merck, Lexeo and Mantle, though no further details were given.